UBS on Danaher (DHR): 'we believe the CPHD platform will continue to see traction as COVID-19 becomes endemic'
Tweet Send to a Friend
UBS analyst Elizabeth Garcia reiterated a Buy rating and $297.00 price target on Danaher (NYSE: DHR).The analyst comments "DHR kicked ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
